Updating results

16 results for dyspepsia

Sort: Relevance | Date

Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)

This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.

Clinical guideline Published September 2014 Last updated October 2019

Dyspepsia and gastro-oesophageal reflux disease

Everything NICE has said on investigating and managing dyspepsia and gastro-oesophageal reflux disease in an interactive flowchart

NICE Pathway Published September 2014 Last updated October 2019

What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond to PPIs or H2 receptor antagonists (H2RAs) despite optimum primary care?

be conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond...

Research recommendation Published November 2019

IQoro for hiatus hernia (MIB176)

Advice on the use of IQoro for hiatus hernia to aid local decision making

Medtech innovation briefing Published March 2019

Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

NICE guideline Published May 2019

Oesophago-gastric cancer (QS176)

This quality standard covers assessing and managing oesophago-gastric cancer in adults. It describes high-quality care in priority areas for improvement.

Quality standard Published December 2018

Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1)

This guideline covers diagnosing and managing gastro-oesophageal reflux disease in children and young people (under 18s). It aims to raise awareness of symptoms that need investigating and treating, and to reassure parents and carers that regurgitation is common in infants under 1 year.

NICE guideline Published January 2015 Last updated October 2019

Past appeals and decisions

- collagenase clostridium histolyticum 30 November 2015 TA007 Dyspepsia - proton pump inhibitors 29 June 2000 TA059 Electroconvulsive...

Published May 2019 Last updated May 2019

Osteoporosis

Everything NICE has said on assessing the risk of, preventing and treating osteoporotic fragility fractures in adults in an interactive flowchart

NICE Pathway Published August 2012 Last updated August 2019

In people who experience symptoms of gastro-oesophageal reflux disease (GORD) or symptoms suggestive of GORD, what patient characteristics, risk factors and predictors indicate when endoscopy is needed to exclude Barrett's oesophagus?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

What is the effectiveness of laparoscopic fundoplication compared with medical management in people with GORD that does not respond to optimal proton pump inhibitor (PPI) treatment?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

What is the clinical effectiveness of double-dose PPIs in people with severe erosive reflux disease (Los Angeles classification grade C/D or Savary–Miller grade 3/4): to reduce severe oesophagitis to control symptoms as maintenance therapy?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

Medicines optimisation

Everything NICE has said on shared decision-making and processes to optimise medicines and support adherence in an interactive flowchart

NICE Pathway Published March 2015 Last updated October 2019

Patisiran for treating hereditary transthyretin amyloidosis (HST10)

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Highly specialised technologies guidance Published August 2019

Bisphosphonates for treating osteoporosis. Bisphosphonates for treating osteoporosis Patient decision aid

bisphosphonate treatment? The most common side effects include: : heartburn and indigestion : pain or stiffness in your muscles, joints...

Published October 2017 Last updated August 2019 Last updated August 2019